Skip to main content
SpringerLink
Log in

Prostanoids cytoprotection for maintaining remission in ulcerative colitis failure of 15(R), 15-methylprostaglandin E2

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

To establish whether the cytoprotective properties of prostanoids can be used for maintaining remission in ulcerative colitis, 24 patients with ulcerative colitis in remission were randomly assigned to receive either 15(R), 15-methyl-PGE2 (200 μg/day) or to continue with sulfasalazine (2.0 g/day) for up to 28 weeks. All patients included were symptom free and sigmoidoscopy and rectal biopsy performed upon entering the trial did not reveal any signs of disease activity. Of the 12 patients who discontinued sulfasalazine and were allocated to receive 15(R), 15-methyl-PGE2, five flared up within the first four weeks and three others had to stop the trial because of severe diarrhea. Because of the high incidence of side effects and flare-up, the other four patients were instructed to stop the trial. In contrast, only two of the 12 sulfasalazine-treated patients flared-up and the other 10 concluded the 28 weeks of the trial symptom free. These results indicate that 15(R), 15-methyl-PGE2 cannot be used to control and support remission in ulcerative colitis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gould SR: Prostaglandins, ulcerative colitis, and sulphasalazine. Lancet 2:988, 1979

    Google Scholar 

  2. Gould SR, Leanard-Jones JE: Production of prostaglandins in ulcerative colitis and their inhibition by sulphasalazine. Gut 17:828, 1976 (abstract)

    Google Scholar 

  3. Gould SR, Brash AR, Connolly ME: Increased prostaglandin production in ulcerative colitis. Lancet 2:98, 1977

    Google Scholar 

  4. Rampton DS, Salden GE, Bhakoo KK, Heinzelmann DI, Youlten LJF: Rectal mucosal prostaglandin E2 release and electrolyte transport in ulcerative colitis. Adv Prostaglandin Thromboxane Res 8:1621–1625, 1980

    Google Scholar 

  5. Smith PR, Dawson DJ, Swan CHJ: Prostaglandin synthetase activity in ulcerative colitis: Effects of treatment with sulphasalazine codeine phosphate and prednisolone. Gut 20:802–805, 1979

    Google Scholar 

  6. Sharon P, Ligumsky M, Rachmilewitz D, Zor U: Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulphasalazine. Gastroenterology 75:638–640, 1978

    Google Scholar 

  7. Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachmilewitz D: Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucose in ulcerative colitis and its inhibition by steroids and sulphasalazine. Gastroenterology 81:444–449, 1981

    Google Scholar 

  8. Collier HOT, Francis AA, McDonald-Gibson WJ, Saed S: Inhibition of prostaglandins biosynthesis by sulphasalazine and its metabolites. Prostaglandins 11:219–225, 1976

    Google Scholar 

  9. Robert A, Nezamis JE, Lancaster C, Hanchar AJ: Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 77(3):433–443, 1979

    Google Scholar 

  10. Vantrappen G, Janssens J, Papiela T, Kulig J, Tytgat GNJ, Huibregtse K, Lambert R, Puchard JP, Robert A: Effect of 15-(R)-15-methyl prostaglandin E2 (Arbaprostil) on the healing of duodenal ulcer. A double-blind multicenter study. Gastroenterology 83:357–363, 1982

    Google Scholar 

  11. Robert A, Nezamis JE, Lancaster C, Hanchar AJ: Prevention through cytoprotection of clindamycin induced colitis in hamsters with 16,16 dimethyl PGE2. Gastroenterology 78:1245, 1980

    Google Scholar 

  12. Hoult JRS, Moore PK: Sulphasalazine is a potent inhibitor of prostaglandin 15 hydroxy dehydrogenase: Possible basis for therapeutic action in ulcerative colitis. Br J Pharmacol 64:6–8, 1978

    Google Scholar 

  13. Hoult JRS, Moore PK: Effects of sulphasalazine and its metabolites on prostaglandin synthesis inactivation and actions on smooth muscle. Br J Pharmacol 68:719–730, 1980

    Google Scholar 

  14. Hansson KA, Sandberg M: Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine. Acta Pharm Swed 10:87–92, 1973

    Google Scholar 

  15. Rachmilewitz D, Ligumsky M, Haimovitz A, Treves AJ: Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory diseases of the bowel. Gastroenterology 82:673–679, 1982

    Google Scholar 

  16. Floman Y, Zor U: Mechanism of steroid action in inflammation. Inhibition of prostaglandin synthesis and release. Prostaglandins 12:403–413, 1976

    Google Scholar 

  17. Ferreira SH, Moncada S, Vane JR: Prostaglandins and signs and symptoms of inflammation.In Prostaglandin Synthetase Inhibitors. HJ Robinson, JR Vane (eds). New York, Raven Press, 1974, pp 175–187

    Google Scholar 

  18. Dissanayake AS, Truelove SC: A controlled therapeutic trial of long term maintenance treatment of ulcerative colitis with sulphasalazine. Gut 14:923–926, 1973

    Google Scholar 

  19. Azad Khan AK, Priis J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895, 1977

    Google Scholar 

  20. Johansson C, Kolberg B, Nordemar R, Bergstrom S: Mucosal protection by prostaglandin E2. Lancet 1:317, 1979

    Google Scholar 

  21. Johansson C, Kolberg B, Nordemar R, Samuelson K, Bergstrom S: Protective effect of prostaglandins E2 in the gastrointestinal tract during indomethacin treatment of rheumatic disease. Gastroenterology 78:479–483, 1980

    Google Scholar 

  22. Kuehl FA Jr, Eyan RW: Prostaglandins, arachidonic acid and inflammation. Science 210:978–984, 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hadassah University Hospital, P.O. Box 12000, Jerusalem, Israel

    Eran Goldin &  Daniel Rachmilewitz

  2. Hebrew University-Hadassah Medical School, Jerusalem, Israel

    Eran Goldin &  Daniel Rachmilewitz

Authors
  1. Eran Goldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Rachmilewitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This study was supported in part by the Upjohn Co., Kalamazoo, Michigan.

Dr. Goldin is a recipient of a fellowship from the Caesarea Foundation, Israel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldin, E., Rachmilewitz, D. Prostanoids cytoprotection for maintaining remission in ulcerative colitis failure of 15(R), 15-methylprostaglandin E2 . Digest Dis Sci 28, 807–811 (1983). https://doi.org/10.1007/BF01296903

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01296903

Keywords

Search

Navigation